Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 606 participants.

Also called NCT02342444

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 606 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02342444
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02342444. Randomized; no masking; primary purpose prevention. Start 2014-02 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Condition
Trauma
Condition
Surgery
Condition
Thromboembolic Events
Intervention (Drug)
Enoxaparin Sodium Injection 30 mg BID
Intervention (Drug)
Enoxaparin Sodium Injection 40 mg QD
Lead sponsor
Oregon Health and Science University (class: other)

Record details

Record id
cardio:ct-nct02342444
Content hash
f851d6e11c499d5ff6adad9396083607c2c873c07f7de9fd3cb112a345af4af6